Europe Streamlines Biosimilar Clinical Trials... K-Biosimilars Ride the Wave
Streamlining of Clinical Procedures for Biosimilars Spreads from the US and Korea to Europe
With the European Medicines Agency (EMA) adopting a recommendation report to streamline biosimilar clinical procedures, the development process is expected to be significantly shortened. Major countries such as the United States and Korea are also joining this regulatory easing trend, which is anticipated to result in substantial benefits for domestic biopharmaceutical companies, including Celltrion and Samsung Bioepis.
According to the Bioeconomy Research Center of the Korea Biotechnology Industry Organization on April 1, the Committee for Medicinal Products for Human Use (CHMP) under the EMA adopted a report on the simplification of biosimilar clinical trials on March 27. The key objective of this report is to reduce the amount of clinical data required for the development and approval of certain biosimilar medicines within the European Union. Since the CHMP typically reviews clinical and safety data of medicines and recommends their approval—decisions that are often interpreted as actual approvals—the impact of this move is significant.
Until now, obtaining approval for a biosimilar required comprehensive comparative clinical trials, which had to demonstrate comparability data, non-clinical in vitro data, pharmacokinetics, pharmacodynamics, safety, and efficacy. However, with advances in analytical science and the accumulation of extensive regulatory experience, the necessity for comparative clinical efficacy and safety data is being newly re-evaluated. For biosimilars where similarity to the original drug has been rigorously established using advanced analytical methods in terms of physicochemical and functional characteristics, it is expected that comparative efficacy clinical studies (CES) will no longer be required during the approval process.
However, comparative clinical pharmacokinetic (PK) studies will remain an essential element in biosimilar development, continuing to provide safety and immunogenicity data. Under certain conditions, drug approval may be granted based solely on similarity demonstrated at the analytical level, with only a limited clinical data package required. This approach allows for a significant simplification of the overall development process without compromising the intrinsic efficacy and safety of the medicine. In its report, the EMA projected that "tailored clinical approaches could be widely applied to the development of most biosimilar candidates."
This regulatory change in Europe is expected to translate into tangible benefits for domestic pharmaceutical and biopharmaceutical companies that focus on biosimilars. According to data compiled by the Bioeconomy Research Center of the Korea Biotechnology Industry Organization, as of the end of March this year, there are a total of 144 biosimilar products that maintain EMA approval. This figure excludes 20 products out of the previously approved 164 that have either lost validity or been voluntarily withdrawn. Looking at the status of marketing authorization holders (MAHs), Celltrion holds 13 products and Samsung Bioepis holds 11, ranking them among the top five alongside major multinationals such as Sandoz, Stada, and Biosimilars Collaboration Ireland. If clinical procedures are further simplified, the cost and time required for research and development can be effectively reduced, thereby enhancing operational efficiency for domestic companies like Celltrion and Samsung Bioepis, which have established multiple product pipelines.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The EMA plans to revise detailed guidelines necessary for biosimilar evaluation in line with the latest CHMP recommendations and to fully implement the streamlined system. The Bioeconomy Research Center stated, "The United States, Canada, Korea, and several other countries are also actively working to simplify biosimilar clinical procedures. This year is expected to become a turning point that brings significant changes to the global regulatory landscape for biosimilar clinical trials and approvals."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.